candoxatril has been researched along with bradykinin in 2 studies
| Studies (candoxatril) | Trials (candoxatril) | Recent Studies (post-2010) (candoxatril) | Studies (bradykinin) | Trials (bradykinin) | Recent Studies (post-2010) (bradykinin) |
|---|---|---|---|---|---|
| 62 | 29 | 5 | 14,195 | 355 | 1,520 |
| Protein | Taxonomy | candoxatril (IC50) | bradykinin (IC50) |
|---|---|---|---|
| B2 bradykinin receptor | Homo sapiens (human) | 0.0018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnal, JF; Bayard, F; Castano, C; Darblade, B; Gourdy, P; Maupas, E; Michel, JB; Mugniot, A | 1 |
| Backes, BJ; Ballaron, SJ; Banfor, PN; Cox, BF; Fryer, RM; Lin, CW; Reinhart, GA; Segreti, J; Trevillyan, JM; von Geldern, TW; Widomski, DL | 1 |
2 other study(ies) available for candoxatril and bradykinin
| Article | Year |
|---|---|
Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Arteriosclerosis; Atrial Natriuretic Factor; Body Weight; Bradykinin; Cholesterol; Cholesterol, HDL; Drug Evaluation, Preclinical; Indans; Male; Mice; Mice, Knockout; Neprilysin; Propionates; Protease Inhibitors; Pyridines; Substance P; Thiazepines; Triglycerides | 2001 |
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.
Topics: Aminopeptidases; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Hypotension; Indans; Lisinopril; Male; Neprilysin; Peptides; Propionates; Pyridines; Rats; Rats, Sprague-Dawley; Thiazepines | 2008 |